TRAVERE THERAPEUTICS INC (TVTX) competitors & alternatives
Health Care · NASDAQ
TRAVERE THERAPEUTICS INC (TVTX)'s top competitors and alternatives — its most similar public companies — include AURINIA PHARMACEUTICALS INC (AUPH), AKEBIA THERAPEUTICS INC (AKBA), Ultragenyx (RARE), SAVARA INC (SVRA), Insmed (INSM), Alnylam Pharmaceuticals (ALNY), HARMONY BIOSCIENCES HLDG INC (HRMY), Jazz Pharmaceuticals (JAZZ), SPRUCE BIOSCIENCES INC (SPRB), OMEROS CORP (OMER), MIRUM PHARMACEUTICALS INC (MIRM) and XERIS BIOPHARMA HOLDINGS INC (XERS). These are TRAVERE THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top TVTX competitors & alternatives
-
AURINIA PHARMACEUTICALS INCAUPHHealth Care
Aurinia is a specialty pharma company commercializing LUPKYNIS, the first oral calcineurin inhibitor approved for lupus nephritis, with strong profitability…
$15.33 (as of 2026-07-22) · market cap $2.0B
-
AKEBIA THERAPEUTICS INCAKBAHealth Care
A biopharmaceutical company specialized in kidney disease therapeutics with a commercial portfolio for anemia and mineral metabolism and a pipeline of rare…
$1.26 (as of 2026-07-22) · market cap $349M
-
UltragenyxRAREHealth Care
Ultragenyx is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for serious, rare, and ultra-rare genetic diseases.
$27.65 (as of 2026-07-22) · market cap $2.8B
-
SAVARA INCSVRAHealth Care
Savara is a clinical-stage biopharmaceutical company dedicated to developing innovative inhalable therapies for rare respiratory diseases.
$5.65 (as of 2026-07-22) · market cap $1.2B
-
InsmedINSMHealth Care
A biopharmaceutical company with approved rare respiratory therapies (ARIKAYCE for MAC lung disease, BRINSUPRI for bronchiectasis) and a pipeline in…
$106.64 (as of 2026-07-22) · market cap $23.4B
-
Alnylam PharmaceuticalsALNYHealth Care
Alnylam is a global leader in RNA interference therapeutics, pioneering a new class of genetic medicines to treat rare and serious diseases.
$266.99 (as of 2026-07-22) · market cap $36.2B
-
HARMONY BIOSCIENCES HLDG INCHRMYHealth Care
Harmony Biosciences is a neuroscience-focused biopharmaceutical company commercializing WAKIX (pitolisant), the first-in-class non-controlled H3 receptor…
$34.86 (as of 2026-07-22) · market cap $2.0B
-
Jazz PharmaceuticalsJAZZHealth Care
A rare-disease biopharmaceutical company with diversified marketed therapies in epilepsy, sleep disorders, and oncology, and an expanding pipeline of…
$250.41 (as of 2026-07-22) · market cap $16.0B
-
SPRUCE BIOSCIENCES INCSPRBHealth Care
Clinical-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for rare lysosomal storage disorders, particularly Sanfilippo…
$44.60 (as of 2026-07-22) · market cap $123M
-
OMEROS CORPOMERHealth Care
A clinical-stage biotech company commercializing complement-pathway inhibitors for rare hematologic and immune diseases, with FDA-approved YARTEMLA for stem…
$9.84 (as of 2026-07-22) · market cap $703M
-
MIRUM PHARMACEUTICALS INCMIRMHealth Care
Mirum is a rare disease biopharmaceutical company commercializing approved bile acid and hepatic therapies while advancing late-stage candidates in cholestatic…
$114.48 (as of 2026-07-22) · market cap $7.0B
-
XERIS BIOPHARMA HOLDINGS INCXERSHealth Care
A commercial-stage biopharma company with three FDA-approved therapies for rare endocrine and neurological diseases and a proprietary injectable drug…
$8.38 (as of 2026-07-22) · market cap $1.5B
Not quite? Describe exactly what you want →
Peers are TRAVERE THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: TRAVERE THERAPEUTICS INC (TVTX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.